

DAFTAR PUSTAKA

1. Robinson M, Syam FA, Abdulah M. Mortality risk factors in acute upper gastrointestinal bleeding. *Indones J Gastroenterol Hepatol Dig Endosc.* 2012; 13:1-37.
2. Lanas A, Garcia-Rodri'guez LA, Polo-Toma's M, Ponce M, Alonso-Abreu I, Perez-Aisa MA, et al. Time trends and impact of upper and lower gastrointestinal bleeding and perforation in clinical practice. *Am J Gastroenterol.* 2009;104:1633-41.
3. Dalton D, Grant-Casey J, Hearnshaw S, Lowe D, Travis S, Rockall T, et al. the UK comparative audit of gastrointestinal bleeding and the use of blood. Oxford, UK: National Blood Service;2007 [cited 2012 Feb 20]. Available from:
http://hospital.blood.co.uk/library/pdf/UGI_Bleed_Audit_Report_transfusion_Extract.pdf
4. Adam V, Barkun A. Estimates of costs of hospital stay for variceal and non-variceal upper gastrointestinal bleeding in the United States. *Value Health.* 2008;11:1-4.
5. Mazen A, Mohammed A, John J. Managing acute upper GI bleeding, preventing recurrences. *Clev Clin J Med.* 2010;105:84-93.
6. Djojodiningrat, Hardjodisastro D. Hematemesis melena. Dalam: Simandibrata M, Setiati S, Alwi I, Maryantoro, Gani RA, Mansjoer A, editor. *Pedoman diagnosis dan terapi di bidang ilmu penyakit dalam.* Jakarta: Pusat Informasi dan Penerbitan Bagian IPD FKUI; 1999:20-4.
7. Djojodiningrat, Hardjodisastro D. Hematemesis Melena. Dalam: Subekti I, Lydia A, Rumende CM, Syam AF, Mansjoer A, Suprohaita, editor. *Prosiding symposium : Penatalaksanaan Kegawatdaruratan di Bidang Ilmu Penyakit Dalam.* Jakarta: Pusat Informasi dan Penerbitan Bagian IPD FKUI; 2001:111-7.

8. Purnomo HD. Endoscopic and clinical features of upper gastrointestinal bleeding in Dr Kariadi Hospital Semarang. Prosiding Symposium: Indonesia Young Clinician Program for World Congress of Gastroenterology; 2005; Montreal Canada.2005.
9. Loren L. Gastrointestinal bleeding. In: Braunwald E, Fauci AS, Dasper DL, hauser SL. Longo DL, Jameson JL, eds. Harrisons's Principle of Internal medicine. 18th ed. USA: McGraw-Hill Companies Inc: 2005; 235.
10. Siregar L, Rani AA, Manan C, Simadibrata M, Makmun D. Clinical profile and outcome of non-variceal upper gastrointestinal bleeding in relation to timing of endoscopic Procedure in patient undergoing elective endoscopy. *Indones J Gastroenterol Hepatol Dig Endosc.* 2011; 12(3):140-5.
11. Wasse H, Gillen LD, Ball AM, Kestenbaum BR, Seliger SL, Sherrard D, Stehman-Breen CO. Risk factors for upper gastrointestinal bleeding among end-stage renal disease patients. *Kidney Int.* 2003; 64: 1455-61.
12. Purnomo HD. Pengelolaan perdarahan akut saluran cerna bagian atas. Dalam: Suharti C, Sugiri, Gasem MH, editor. Pertemuan ilmiah tahunan XIV PAPDI; 2010 24-26 sept. Semarang (Indonesia): Badan Penerbit Universitas Diponegoro; 2010:45-55.
13. Gilbert DA, Silverstein FE. Acute upper gastrointestinal bleeding. In: Sivak MV, Schleutermann DA, eds. *Gastroenterologic endoscopy.* 2nd ed. Philadelphia: WB Saunders; 2000. 284-300.
14. Supriyono M. Faktor-faktor risiko yang berpengaruh terhadap kejadian penyakit jantung koroner pada kelompok usia ≤ 45 tahun: studi kasus di RSUP Dr Kariadi dan RS telogorejo Semarang [Thesis]. Semarang: Universitas Diponegoro; 2008.
15. Kligenberg K. Hansson GK. Treating inflammation in atherosclerotic cardiovascular disease : emerging therapies. *Eur Heart J.* 2009;30:2838-3844.
16. Tanuwidjojo S. Peranan clopidogrel pada penyakit jantung iskemia kronik. Dalam: Suharti C, Sugiri, gasem MH, editor. Pertemuan ilmiah tahunan

- XIV PAPDI; 2010 24-26 Sept. Semarang (Indonesia): Badan Penerbit Universitas Diponegoro; 2010:289-95.
17. Ng F, Wong SY, Lau YK, Kng PLC. Upper gastrointestinal bleeding during Anti-platelet. *Hong Kong Med J.* 2008; 13(3):27-39.
 18. Gorelick PB, Born GVR, Agostino RPD, Hanley DF, Moye L, Pepine CJ. Therapeutic benefit: aspirin revisited in light of the introduction of clopidogrel. *Am Heart J.* 1999; 30:1716-21.
 19. Derry S, Loke YK. Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis. *Br Med J.* 2000; 321:1183-7.
 20. Becker J,C, Domsche W, Pohle T. current approach to prevent NSAID induced gastrophathy-COX selectivity and beyond. *Br J Clin Pharm.* 2004; 58(6):587-600.
 21. Serano P, Lanas A, Arroyo MT, Ferreira IJ. Risk of upper gastrointestinal bleeding in patients taking low-dose aspirin for the prevention of cardiovascular disease. *Aliment Pharmacol Ther.* 2002; 16:1945-53.
 22. Djojoningrat D. Perdarahan saluran cerna bagian atas (hematemesis melena). Dalam: Rani AA, K MS, Syam AF, editor. *Buku ajar gastroenterology.* Edisi ke-1. Jakarta: Pusat penerbit Ilmu Penyakit Dalam FK UI; 2011: 33-44.
 23. Adi P. Pengelolaan perdarahan saluran cerna bagian atas. Dalam: Sudoyo AW, Setiyohadi B, Alwi I, K MS, Setiati S, editor. *Buku ajar ilmu penyakit dalam.* Edisi ke-5. Jakarta: Pusat Penerbit Ilmu Penyakit Dalam FK UI; 2010: 447-53.
 24. Maduseno S. Rekomendasi terbaru perdarahan ulkus peptic, “konsensus internasional”. Dalam: Purnomo HD, Hirlan, editor. *Semarang Gastroenterohepatology update 2011 “Current issues in gastroenterohepatology: from theory to clinical Practice; 2011 Apr 8-10”.* Semarang (Indonesia): Badan Penerbit Universitas Diponegoro;2011:33-51.
 25. Green BT, Rockey DC. Acute gastrointestinal bleeding. *Semin Gastrointest Dis.* 2003;14(2):44-65.

26. Syam A.F, Abdullah M, Makmun D, Simandabrata MK, Djojoningrat D, M, et al. The cause of upper gastrointestinal bleeding in the national referral hospital: evaluation on upper gastrointestinal bleeding tract endoscopic result in five years period. *Indones J Gastroenterol Hepatol Dig Endosc.* 2005; 6(3):71-4.
27. Soll AH, Graham YD. Peptic ulcer disease. In: Yamada T, ed. *Textbook of gastroenterology.* 5th ed. 2009; 936-46.
28. Shirazian S, Radhakrishnan J. Gastrointestinal symptoms in patients undergoing peritoneal dialysis: Multivariate analysis of correlated factors. *World J Gastroenterol.*2010;16(22):2812-7
29. Saeed F, Agrawal N, Greenberg E, Holley JL. Lower gastrointestinal bleeding in chronic hemodialysis patients. *Int J Nephrol.*2011;20(11):272-535
30. Kaaroud H, Ben FL, Beji S, Boubaker K, Hedri H, Ben HF. Gastrointestinal angiodysplasia in chronic renal failure. *Saudi J kidney Dis Transplant.*2008;19(5):809-12.
31. Wolf PA, D'Agostino RB, Belanger AJ, Kannel WB. Probability of stroke: a risk profile from the Framingham Study. *Stroke.*1991;22:312-8.
32. Rockall TA, Logan RFA, Northfield TC. Risk assessment after acute upper gastrointestinal haemorrhage. *Gut.*1996;38:316-21.
33. Turner JR. The gastrointestinal tract. In: Kumar V, Abbas A.K, Fausto N, Aster J.C. *Robbins and cotran pathologis basis of disease.* 8th ed. Philadelphia: Elsevier Saunders Inc; 2010; 763-70.
34. Djokomoeljanto R. Clinical aspects of diabetes mellitus and its complications. *Pertemuan ilmiah tahunan XIV PAPDI; 2010 24-26 sept 2010; Semarang (Indonesia): Badan Penerbit Universitas Diponegoro; 2010:1-11.*
35. Silverstein FE, GD, Tedesco FJ, Buenger NK, Persing J. The national ASGE survey on upper gastrointestinal bleeding . II. Clinical prognostic factors. *Gastrointest endosc.* 1981; 27:80-93.

36. Corley DA SA, Wolf M, Cook EF, Lee TH. Early indicators of prognosis in upper gastrointestinal hemorrhage. *Am J Gastroenterol.* 1998; 93:336-40.
37. Aljebreen AM FC, Barkun AN. Nasogastric aspirate predicts high-risk endoscopic lesions in patients with acute upper-GI bleeding. *Gastrointest Endosc.* 2004; 59: 17.
38. Chak A CG, Llyod LE, Kolz CS, Barnhart BA, Wong RC. Effectiveness of endoscopy in patients admitted to the intensive care unit with upper GI hemorrhage. *Gastrointest endosc.* 2001; 53:6-13.
39. Grace HE. Approach to the patient with gross gastrointestinal bleeding. In: Yamada T, ed. *Atlas of Gastroenterology.* 4th ed; 2009; 1-9.
40. Gralnek I.M, Barkun A.N, Bardou M. Management of acute bleeding from a peptic ulcer. *N Engl J Med.* 2008; 359:928-37.
41. OECD/WHO 2012. Mortality from cardiovascular disease. *Health at a Glance: Asia/Pacific 2012*, OECD Publishing. Available from: <http://dx.doi.org/10.1787/9789264183902-8-en>.
42. Brown JR, O'connor GT. Coronary heart disease and prevention in the united states. *N Eng J Med.* 2010; 362: 2150-3.
43. Von Rokitansky C. A manual of pathological anatomy. In: day, Edward G, eds. London: Sydenham Society; 1852: 4:261.
44. Duguid JB. Thrombosis as a factor in the pathogenesis of coronary atherosclerosis. *J Pathol Bacteriol.* 1946; 58:207-12.
45. Fuster V, Badimon L, Badimon J.J, Chesebro J.H. Mechanisme of disease: The pathogenesis of coronary artery disease and the acute coronary syndromes. *N Engl J Med.* 1992; 326:242-50.
46. Ross R. The pathogenesis of atherosclerosis-an update. *N Engl J Med.* 1986; 314:448-500.
47. Gawaz M, et al. Platelets in inflammation and atherogenesis. *J Clin Invest.* 2005; 115:3378-84.
48. Alwi I. Infark miokard akut dengan elevasi ST. Dalam: Sudoyo AW, Setiyohadi B, Alwi I, K MS, Setiati S, editor. *Buku Ajar Ilmu Penyakit*

- Dalam. Edisi ke-5. Jakarta: Pusat Penerbit Ilmu Penyakit Dalam FK UI; 2010: 1741-57.
49. Huon H. Gray, Keith D. Dawkins, John M. Morgan, Iain A. Simpson. Lecture notes cardiology. 4th ed. Jakarta: Erlangga Medical Series. 2002: 107-50.
 50. Centers for Disease Control and prevention. Moving into action: promoting heart healthy and stroke-free communities (health care leaders). Atlanta, GA: U.S. Department of Health and Human Services; 2005. Available from: www.cdc.gov/cvh
 51. Dewoto HR. Antikoagulan, antitrombotik, trombolitik dan hemostatik. Dalam: Gunawan SG, Nafrialdi RS, Elisabeth editor. Farmakologi dan terapi. Edisi ke-5. Jakarta: Balai Penerbit FKUI; 2008; 804-19.
 52. O'Reily R.A. Obat yang digunakan untuk gangguan koagulasi. Dalam: Agoes A, editor. Farmakologi dasar dan klinik. Edisi ke-6. Jakarta: Penerbit Buku Kedokteran EGC. 1997: 528-43.
 53. Knight J.C. Antiplatelet treatment in stable coronary artery disease. *Heart*. 2003; 89:1273-78.
 54. Cannon PC, Braunwald E. Unstable angina and non-ST-segment elevation myocardial infarction. In: Longo DL, Kasper LD, Jameson LJ, Fauci AS, Hauser SL, Loscalzo J, eds. *Harrison's principles of internal medicine*. 18th ed. USA: McGraw-Hill Companies Inc: 2012; 2015-21
 55. Neuman F. Induction of cytokine expression in leucocytes by binding of thrombin stimulated platelets. *Circulation*. 1997; 95:2387-404.
 56. Herman A. Platelet CD40 Ligand subcellular localization, regulation of expression and inhibition by clopidogrel. *Platelets*. 2001; 12:74-8.
 57. Hadi S. Bagaimana memilih OAINS yang aman. Dalam: Hirlan, Purnomo HD, editor. Semarang Gastroenterohepatology update 2011 "Current issues in gastroenterohepatology: from theory to clinical Practice; 2011 Apr 8-10". Semarang (Indonesia): Badan Penerbit Universitas Diponegoro; 2011:67-73.

58. Shah AA, Fitzgerald DJ, and Murray FE. Non steroidal anti inflammatory drugs (NSAIDS) and gastro intestinal toxicity: current issues. In *J Med*. 1999; 168(4):242-7.
59. Lanza FL. A review of gastric ulcer and gastroduodenal injury in normal volunteers receiving aspirin and other non-steroidal anti-inflammatory drugs. *Scand J Gastroenterol*. 1988; 24(163): 24-31.
60. Newton JL. A review of improving the gastrointestinal tolerability of aspirin in older people. *Clin Interv Aging*. 2006; 1(1):33-9.
61. Mourkarbel GV, Signorovitch JE, Pfeffer MA, McMurray J, White HD, Maggioni AP, et al. gastrointestinal bleeding in high risk survivors of myocardial infarction : the VALIANT Trial. *Eur Heart J*. 2009;(30):2226-32.
62. Thomson ICR, Teo E. The changing face of non-variceal, upper gastrointestinal hemorrhage. *J Gastroenterol Hepatol*. 2007; (22): 13-7.
63. Noolima G, Vallurupalli MD, Samuel Z, Goldhaber M. Gastrointestinal complications of dual antiplatelet therapy. *Circulation*. 2006;(113):655-58.
64. A L, Rodriguez G, Lin KJ, Johansson S, Diaz SH. Risk of upper gastrointestinal bleeding with low-dose acetylsalicylic acid alone and in combination with clopidogrel and other medications. *Circulation*. 2011;123:1108-15.
65. Ziegellin M, Hoschtitzky A, Dunning J, Hooper T. Does clopidogrel rather than aspirin plus a proton-pump inhibitor reduce the frequency of gastrointestinal complications after cardiac surgery?. *Interact Cardiovasc Thorac Surg*. 2007;534-7.
66. Wong SY, Chang CM, Chen WH, KNG C. High incidence of clopidogrel-associated gastrointestinal bleeding in patients with previous peptic ulcer disease. *Aliment Pharmacol Ther*. 2003;(18):443-9.
67. Tan VP, Yan BP, Kieman TJ, Ajani AE. Risk and management of upper gastrointestinal bleeding associated with prolonged dual-antiplatelet therapy after percutaneous coronary intervention. *Cardiovasc Revasc Med*. 2009:36-44.

LAMPIRAN

OUTPUT SPSS

SPSS Deskriptif

KASUS

Jenis Kelamin Pasien

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Laki-Laki	30	75.0	75.0	75.0
	Perempuan	10	25.0	25.0	100.0
	Total	40	100.0	100.0	

Kategori Usia

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	<64	18	45.0	45.0	45.0
	>=64	22	55.0	55.0	100.0
	Total	40	100.0	100.0	

Aspirin

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Ya	35	87.5	87.5	87.5
	Tidak	5	12.5	12.5	100.0
	Total	40	100.0	100.0	

Clopidogrel

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Ya	17	42.5	42.5	42.5
	Tidak	23	57.5	57.5	100.0
	Total	40	100.0	100.0	

kategori Dosis Aspirin

	Frequency	Percent	Valid Percent	Cumulative Percent
Valid <=120	32	80.0	80.0	80.0
>120	8	20.0	20.0	100.0
Total	40	100.0	100.0	

Kategori Dosis Clopidogrel

	Frequency	Percent	Valid Percent	Cumulative Percent
Valid <=38	23	57.5	57.5	57.5
>38	17	42.5	42.5	100.0
Total	40	100.0	100.0	

Kategori Durasi Aspirin

	Frequency	Percent	Valid Percent	Cumulative Percent
Valid <=69	33	82.5	82.5	82.5
>69	7	17.5	17.5	100.0
Total	40	100.0	100.0	

Kategori Durasi Clopidogrel

	Frequency	Percent	Valid Percent	Cumulative Percent
Valid <=31	36	90.0	90.0	90.0
>31	4	10.0	10.0	100.0
Total	40	100.0	100.0	

Gejala Klinis

	Frequency	Percent	Valid Percent	Cumulative Percent
Valid Dispepsia	3	7.5	7.5	7.5
Hematemesis	6	15.0	15.0	22.5
Melena	20	50.0	50.0	72.5
Hematemesis dan Melena	11	27.5	27.5	100.0
Total	40	100.0	100.0	

Gastritis Erosif

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Ya	27	67.5	67.5	67.5
	Tidak	13	32.5	32.5	100.0
	Total	40	100.0	100.0	

Gastritis Peptik

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Ya	1	2.5	2.5	2.5
	Tidak	39	97.5	97.5	100.0
	Total	40	100.0	100.0	

Gastropathy NSAID

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Ya	8	20.0	20.0	20.0
	Tidak	32	80.0	80.0	100.0
	Total	40	100.0	100.0	

Ulkus Gaster Forest III

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Ya	7	17.5	17.5	17.5
	Tidak	33	82.5	82.5	100.0
	Total	40	100.0	100.0	

Ulkus Duodenum Forest III

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Ya	1	2.5	2.5	2.5
	Tidak	39	97.5	97.5	100.0
	Total	40	100.0	100.0	

Ulkus Peptikum

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Ya	3	7.5	7.5	7.5
	Tidak	37	92.5	92.5	100.0
	Total	40	100.0	100.0	

Pemakaian OAINS

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Ya	12	30.0	30.0	30.0
	Tidak	28	70.0	70.0	100.0
	Total	40	100.0	100.0	

Merokok

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Ya	7	17.5	17.5	17.5
	Tidak	33	82.5	82.5	100.0
	Total	40	100.0	100.0	

Gastritis

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Ya	7	17.5	17.5	17.5
	Tidak	33	82.5	82.5	100.0
	Total	40	100.0	100.0	

Diabetes Mellitus

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Ya	9	22.5	22.5	22.5
	Tidak	31	77.5	77.5	100.0
	Total	40	100.0	100.0	

Proton Pump Inhibitor

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Ya	15	37.5	37.5	37.5
	Tidak	25	62.5	62.5	100.0
	Total	40	100.0	100.0	

Histamine H2 receptor

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Ya	13	32.5	32.5	32.5
	Tidak	27	67.5	67.5	100.0
	Total	40	100.0	100.0	

Hipertensi

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Ya	25	62.5	62.5	62.5
	Tidak	15	37.5	37.5	100.0
	Total	40	100.0	100.0	

Chronic Kidney Disease

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Ya	11	27.5	27.5	27.5
	Tidak	29	72.5	72.5	100.0
	Total	40	100.0	100.0	

Chronic Heart Failure

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Ya	5	12.5	12.5	12.5
	Tidak	35	87.5	87.5	100.0
	Total	40	100.0	100.0	

KONTROL**Jenis Kelamin Pasien**

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Laki-Laki	33	82.5	82.5	82.5
	Perempuan	7	17.5	17.5	100.0
	Total	40	100.0	100.0	

Kategori Usia

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	<64	20	50.0	50.0	50.0
	>=64	20	50.0	50.0	100.0
	Total	40	100.0	100.0	

Aspirin

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Ya	38	95.0	95.0	95.0
	Tidak	2	5.0	5.0	100.0
	Total	40	100.0	100.0	

Clopidogrel

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Ya	30	75.0	75.0	75.0
	Tidak	10	25.0	25.0	100.0
	Total	40	100.0	100.0	

Kategori Dosis Aspirin

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	<=120	24	60.0	60.0	60.0
	>120	16	40.0	40.0	100.0
	Total	40	100.0	100.0	

Kategori Dosis Clopidogrel

	Frequency	Percent	Valid Percent	Cumulative Percent
Valid <=38	10	25.0	25.0	25.0
>38	30	75.0	75.0	100.0
Total	40	100.0	100.0	

kategori Durasi Aspirin

	Frequency	Percent	Valid Percent	Cumulative Percent
Valid <=69	9	22.5	22.5	22.5
>69	31	77.5	77.5	100.0
Total	40	100.0	100.0	

Kategori Durasi Clopidogrel

	Frequency	Percent	Valid Percent	Cumulative Percent
Valid <=31	12	30.0	30.0	30.0
>31	28	70.0	70.0	100.0
Total	40	100.0	100.0	

Pemakaian OAINS

	Frequency	Percent	Valid Percent	Cumulative Percent
Valid Ya	8	20.0	20.0	20.0
Tidak	32	80.0	80.0	100.0
Total	40	100.0	100.0	

Merokok

	Frequency	Percent	Valid Percent	Cumulative Percent
Valid Ya	13	32.5	32.5	32.5
Tidak	27	67.5	67.5	100.0
Total	40	100.0	100.0	

Gastritis

	Frequency	Percent	Valid Percent	Cumulative Percent
Valid Ya	8	20.0	20.0	20.0
Tidak	32	80.0	80.0	100.0
Total	40	100.0	100.0	

Diabetes Mellitus

	Frequency	Percent	Valid Percent	Cumulative Percent
Valid Ya	13	32.5	32.5	32.5
Tidak	27	67.5	67.5	100.0
Total	40	100.0	100.0	

Proton Pump Inhibitor

	Frequency	Percent	Valid Percent	Cumulative Percent
Valid Ya	18	45.0	45.0	45.0
Tidak	22	55.0	55.0	100.0
Total	40	100.0	100.0	

Histamine H2 receptor

	Frequency	Percent	Valid Percent	Cumulative Percent
Valid Ya	11	27.5	27.5	27.5
Tidak	29	72.5	72.5	100.0
Total	40	100.0	100.0	

Hipertensi

	Frequency	Percent	Valid Percent	Cumulative Percent
Valid Ya	35	87.5	87.5	87.5
Tidak	5	12.5	12.5	100.0
Total	40	100.0	100.0	

Chronic Kidney Disease

	Frequency	Percent	Valid Percent	Cumulative Percent
Valid Ya	10	25.0	25.0	25.0
Tidak	30	75.0	75.0	100.0
Total	40	100.0	100.0	

Chronic Heart Failure

	Frequency	Percent	Valid Percent	Cumulative Percent
Valid Ya	7	17.5	17.5	17.5
Tidak	33	82.5	82.5	100.0
Total	40	100.0	100.0	

UJI Chi-Square**Jenis Kelamin Pasien * Perdarahan SCBA Crosstabulation**

			Perdarahan SCBA		Total
			Ya	Tidak	
Jenis Kelamin Pasien	Laki-Laki	Count	30	33	63
		Expected Count	31.5	31.5	63.0
		% within Perdarahan SCBA	75.0%	82.5%	78.8%
	Perempuan	Count	10	7	17
		Expected Count	8.5	8.5	17.0
		% within Perdarahan SCBA	25.0%	17.5%	21.3%
Total	Count	40	40	80	
	Expected Count	40.0	40.0	80.0	
	% within Perdarahan SCBA	100.0%	100.0%	100.0%	

Chi-Square Tests

	Value	df	Asymp. Sig. (2-sided)	Exact Sig. (2-sided)	Exact Sig. (1-sided)
Pearson Chi-Square	.672 ^a	1	.412		
Continuity Correction ^b	.299	1	.585		
Likelihood Ratio	.675	1	.411		
Fisher's Exact Test				.586	.293
Linear-by-Linear Association	.664	1	.415		
N of Valid Cases	80				

a. 0 cells (.0%) have expected count less than 5. The minimum expected count is 8.50.

b. Computed only for a 2x2 table

Risk Estimate

	Value	95% Confidence Interval	
		Lower	Upper
Odds Ratio for Jenis Kelamin Pasien (Laki-Laki / Perempuan)	.636	.215	1.883
For cohort Perdarahan SCBA = Ya	.810	.504	1.301
For cohort Perdarahan SCBA = Tidak	1.272	.688	2.353
N of Valid Cases	80		

Perdarahan SCBA * Kategori Usia Crosstabulation

			Kategori Usia		Total
			<64	>=64	
Perdarahan SCBA	Ya	Count	18	22	40
		Expected Count	19.0	21.0	40.0
		% within Kategori Usia	47.4%	52.4%	50.0%
	Tidak	Count	20	20	40
		Expected Count	19.0	21.0	40.0
		% within Kategori Usia	52.6%	47.6%	50.0%
Total	Count	38	42	80	
	Expected Count	38.0	42.0	80.0	
	% within Kategori Usia	100.0%	100.0%	100.0%	

Chi-Square Tests

	Value	df	Asymp. Sig. (2-sided)	Exact Sig. (2-sided)	Exact Sig. (1-sided)
Pearson Chi-Square	.201 ^a	1	.654		
Continuity Correction ^b	.050	1	.823		
Likelihood Ratio	.201	1	.654		
Fisher's Exact Test				.823	.412
Linear-by-Linear Association	.198	1	.656		
N of Valid Cases	80				

a. 0 cells (.0%) have expected count less than 5. The minimum expected count is 19.00.

b. Computed only for a 2x2 table

Risk Estimate

	Value	95% Confidence Interval	
		Lower	Upper
Odds Ratio for Perdarahan SCBA (Ya / Tidak)	.818	.340	1.970
For cohort Kategori Usia = <64	.900	.567	1.428
For cohort Kategori Usia = >=64	1.100	.724	1.671
N of Valid Cases	80		

Perdarahan SCBA * Aspirin Crosstabulation

			Aspirin		Total
			Ya	Tidak	
Perdarahan SCBA	Ya	Count	35	5	40
		Expected Count	36.5	3.5	40.0
		% within Aspirin	47.9%	71.4%	50.0%
Perdarahan SCBA	Tidak	Count	38	2	40
		Expected Count	36.5	3.5	40.0
		% within Aspirin	52.1%	28.6%	50.0%
Total		Count	73	7	80
		Expected Count	73.0	7.0	80.0
		% within Aspirin	100.0%	100.0%	100.0%

Chi-Square Tests

	Value	df	Asymp. Sig. (2-sided)	Exact Sig. (2-sided)	Exact Sig. (1-sided)
Pearson Chi-Square	1.409 ^a	1	.235		
Continuity Correction ^b	.626	1	.429		
Likelihood Ratio	1.452	1	.228		
Fisher's Exact Test				.432	.216
Linear-by-Linear Association	1.391	1	.238		
N of Valid Cases	80				

a. 2 cells (50.0%) have expected count less than 5. The minimum expected count is 3.50.

b. Computed only for a 2x2 table

Risk Estimate

	Value	95% Confidence Interval	
		Lower	Upper
Odds Ratio for Perdarahan SCBA (Ya / Tidak)	.368	.067	2.023
For cohort Aspirin = Ya	.921	.803	1.056
For cohort Aspirin = Tidak	2.500	.515	12.139
N of Valid Cases	80		

Perdarahan SCBA * Clopidogrel Crosstabulation

			Clopidogrel		Total
			Ya	Tidak	
Perdarahan SCBA	Ya	Count	17	23	40
		Expected Count	23.5	16.5	40.0
		% within Clopidogrel	36.2%	69.7%	50.0%
	Tidak	Count	30	10	40
		Expected Count	23.5	16.5	40.0
		% within Clopidogrel	63.8%	30.3%	50.0%
Total	Count	47	33	80	
	Expected Count	47.0	33.0	80.0	
	% within Clopidogrel	100.0%	100.0%	100.0%	

Chi-Square Tests

	Value	df	Asymp. Sig. (2-sided)	Exact Sig. (2- sided)	Exact Sig. (1- sided)
Pearson Chi-Square	8.717 ^a	1	.003		
Continuity Correction ^b	7.427	1	.006		
Likelihood Ratio	8.906	1	.003		
Fisher's Exact Test				.006	.003
Linear-by-Linear Association	8.608	1	.003		
N of Valid Cases	80				

a. 0 cells (.0%) have expected count less than 5. The minimum expected count is 16.50.

b. Computed only for a 2x2 table

Risk Estimate

	Value	95% Confidence Interval	
		Lower	Upper
Odds Ratio for Perdarahan SCBA (Ya / Tidak)	.246	.095	.638
For cohort Clopidogrel = Ya	.567	.379	.847
For cohort Clopidogrel = Tidak	2.300	1.263	4.188
N of Valid Cases	80		

Perdarahan SCBA * Kategori Dosis Aspirin Crosstabulation

			Kategori Dosis Aspirin		Total
			<=120	>120	
Perdarahan SCBA	Ya	Count	32	8	40
		Expected Count	28.0	12.0	40.0
		% within Kategori Dosis Aspirin	57.1%	33.3%	50.0%
	Tidak	Count	24	16	40
		Expected Count	28.0	12.0	40.0
		% within Kategori Dosis Aspirin	42.9%	66.7%	50.0%
Total	Count	56	24	80	
	Expected Count	56.0	24.0	80.0	
	% within Kategori Dosis Aspirin	100.0%	100.0%	100.0%	
	Aspirin				

Chi-Square Tests

	Value	df	Asymp. Sig. (2-sided)	Exact Sig. (2-sided)	Exact Sig. (1-sided)
Pearson Chi-Square	3.810 ^a	1	.051		
Continuity Correction ^b	2.917	1	.088		
Likelihood Ratio	3.865	1	.049		
Fisher's Exact Test				.087	.043
Linear-by-Linear Association	3.762	1	.052		
N of Valid Cases	80				

a. 0 cells (.0%) have expected count less than 5. The minimum expected count is 12.00.

b. Computed only for a 2x2 table

Risk Estimate

	Value	95% Confidence Interval	
		Lower	Upper
Odds Ratio for Perdarahan SCBA (Ya / Tidak)	2.667	.981	7.250
For cohort Kategori Dosis Aspirin = <=120	1.333	.991	1.794
For cohort Kategori Dosis Aspirin = >120	.500	.242	1.034
N of Valid Cases	80		

Perdarahan SCBA * Kategori Dosis Clopidogrel Crosstabulation

			Kategori Dosis Clopidogrel		Total
			<=38	>38	
Perdarahan SCBA Ya	Count	23	17	40	
	Expected Count	16.5	23.5	40.0	
	% within Kategori Dosis Clopidogrel	69.7%	36.2%	50.0%	
Perdarahan SCBA Tidak	Count	10	30	40	
	Expected Count	16.5	23.5	40.0	
	% within Kategori Dosis Clopidogrel	30.3%	63.8%	50.0%	
Total	Count	33	47	80	
	Expected Count	33.0	47.0	80.0	
	% within Kategori Dosis Clopidogrel	100.0%	100.0%	100.0%	

Chi-Square Tests

	Value	df	Asymp. Sig. (2-sided)	Exact Sig. (2-sided)	Exact Sig. (1-sided)
Pearson Chi-Square	8.717 ^a	1	.003		
Continuity Correction ^b	7.427	1	.006		
Likelihood Ratio	8.906	1	.003		
Fisher's Exact Test				.006	.003
Linear-by-Linear Association	8.608	1	.003		
N of Valid Cases	80				

a. 0 cells (.0%) have expected count less than 5. The minimum expected count is 16.50.

b. Computed only for a 2x2 table

Risk Estimate

	Value	95% Confidence Interval	
		Lower	Upper
Odds Ratio for Perdarahan SCBA (Ya / Tidak)	4.059	1.568	10.510
For cohort Kategori Dosis Clopidogrel = <=38	2.300	1.263	4.188
For cohort Kategori Dosis Clopidogrel = >38	.567	.379	.847
N of Valid Cases	80		

Perdarahan SCBA * Kategori Durasi Aspirin Crosstabulation

			Kategori Durasi Aspirin		Total
			<=69	>69	
Perdarahan SCBA	Ya	Count	33	7	40
		Expected Count	21.0	19.0	40.0
		% within Perdarahan SCBA	82.5%	17.5%	100.0%
		% within Kategori Durasi Aspirin	78.6%	18.4%	50.0%
Tidak		Count	9	31	40
		Expected Count	21.0	19.0	40.0
		% within Perdarahan SCBA	22.5%	77.5%	100.0%
		% within Kategori Durasi Aspirin	21.4%	81.6%	50.0%
Total		Count	42	38	80
		Expected Count	42.0	38.0	80.0
		% within Perdarahan SCBA	52.5%	47.5%	100.0%
		% within Kategori Durasi Aspirin	100.0%	100.0%	100.0%

Chi-Square Tests

	Value	df	Asymp. Sig. (2-sided)	Exact Sig. (2-sided)	Exact Sig. (1-sided)
Pearson Chi-Square	28.872 ^a	1	.000		
Continuity Correction ^b	26.516	1	.000		
Likelihood Ratio	30.952	1	.000		
Fisher's Exact Test				.000	.000
Linear-by-Linear Association	28.511	1	.000		
N of Valid Cases	80				

a. 0 cells (.0%) have expected count less than 5. The minimum expected count is 19.00.

b. Computed only for a 2x2 table

Risk Estimate

	Value	95% Confidence Interval	
		Lower	Upper
Odds Ratio for Perdarahan SCBA (Ya / Tidak)	16.238	5.391	48.914
For cohort Kategori Durasi Aspirin = <=69	3.667	2.027	6.632
For cohort Kategori Durasi Aspirin = >69	.226	.113	.452
N of Valid Cases	80		

Perdarahan SCBA * Kategori Durasi Clopidogrel Crosstabulation

			Kategori Durasi Clopidogrel		Total
			<=31	>31	
Perdarahan SCBA	Ya	Count	36	4	40
		Expected Count	24.0	16.0	40.0
		% within Perdarahan SCBA	90.0%	10.0%	100.0%
		% within Kategori Durasi Clopidogrel	75.0%	12.5%	50.0%
Tidak	Count	12	28	40	
	Expected Count	24.0	16.0	40.0	
	% within Perdarahan SCBA	30.0%	70.0%	100.0%	
	% within Kategori Durasi Clopidogrel	25.0%	87.5%	50.0%	
Total	Count	48	32	80	
	Expected Count	48.0	32.0	80.0	
	% within Perdarahan SCBA	60.0%	40.0%	100.0%	
	% within Kategori Durasi Clopidogrel	100.0%	100.0%	100.0%	

Chi-Square Tests

	Value	df	Asymp. Sig. (2-sided)	Exact Sig. (2-sided)	Exact Sig. (1-sided)
Pearson Chi-Square	30.000 ^a	1	.000		
Continuity Correction ^b	27.552	1	.000		
Likelihood Ratio	32.806	1	.000		
Fisher's Exact Test				.000	.000
Linear-by-Linear Association	29.625	1	.000		
N of Valid Cases	80				

a. 0 cells (.0%) have expected count less than 5. The minimum expected count is 16.00.

b. Computed only for a 2x2 table

Pemakaian OAINS * Perdarahan SCBA Crosstabulation

			Perdarahan SCBA		Total
			Ya	Tidak	
Pemakaian OAINS	Ya	Count	12	8	20
		Expected Count	10.0	10.0	20.0
		% within Perdarahan SCBA	30.0%	20.0%	25.0%
	Tidak	Count	28	32	60
		Expected Count	30.0	30.0	60.0
		% within Perdarahan SCBA	70.0%	80.0%	75.0%
Total		Count	40	40	80
		Expected Count	40.0	40.0	80.0
		% within Perdarahan SCBA	100.0%	100.0%	100.0%

Chi-Square Tests

	Value	df	Asymp. Sig. (2-sided)	Exact Sig. (2-sided)	Exact Sig. (1-sided)
Pearson Chi-Square	1.067 ^a	1	.302		
Continuity Correction ^b	.600	1	.439		
Likelihood Ratio	1.072	1	.300		
Fisher's Exact Test				.439	.220
Linear-by-Linear Association	1.053	1	.305		
N of Valid Cases	80				

a. 0 cells (.0%) have expected count less than 5. The minimum expected count is 10.00.

Risk Estimate

	Value	95% Confidence Interval	
		Lower	Upper
Odds Ratio for Pemakaian OAINS (Ya / Tidak)	1.714	.613	4.794
For cohort Perdarahan SCBA = Ya	1.286	.821	2.014
For cohort Perdarahan SCBA = Tidak	.750	.417	1.348
N of Valid Cases	80		

Merokok * Perdarahan SCBA Crosstabulation

			Perdarahan SCBA		Total
			Ya	Tidak	
Merokok	Ya	Count	7	13	20
		Expected Count	10.0	10.0	20.0
		% within Perdarahan SCBA	17.5%	32.5%	25.0%
	Tidak	Count	33	27	60
		Expected Count	30.0	30.0	60.0
		% within Perdarahan SCBA	82.5%	67.5%	75.0%
Total		Count	40	40	80
		Expected Count	40.0	40.0	80.0

Merokok * Perdarahan SCBA Crosstabulation

			Perdarahan SCBA		Total
			Ya	Tidak	
Merokok	Ya	Count	7	13	20
		Expected Count	10.0	10.0	20.0
		% within Perdarahan SCBA	17.5%	32.5%	25.0%
Merokok	Tidak	Count	33	27	60
		Expected Count	30.0	30.0	60.0
		% within Perdarahan SCBA	82.5%	67.5%	75.0%
Total		Count	40	40	80
		Expected Count	40.0	40.0	80.0
		% within Perdarahan SCBA	100.0%	100.0%	100.0%

Chi-Square Tests

	Value	df	Asymp. Sig. (2-sided)	Exact Sig. (2-sided)	Exact Sig. (1-sided)
Pearson Chi-Square	2.400 ^a	1	.121		
Continuity Correction ^b	1.667	1	.197		
Likelihood Ratio	2.429	1	.119		
Fisher's Exact Test				.196	.098
Linear-by-Linear Association	2.370	1	.124		
N of Valid Cases	80				

a. 0 cells (.0%) have expected count less than 5. The minimum expected count is 10.00.

b. Computed only for a 2x2 table

Risk Estimate

	Value	95% Confidence Interval	
		Lower	Upper
Odds Ratio for Merokok (Ya / Tidak)	.441	.154	1.259
For cohort Perdarahan SCBA = Ya	.636	.336	1.206
For cohort Perdarahan SCBA = Tidak	1.444	.943	2.212
N of Valid Cases	80		

Gastritis * Perdarahan SCBA Crosstabulation

			Perdarahan SCBA		Total
			Ya	Tidak	
gastritis	Ya	Count	7	8	15
		Expected Count	7.5	7.5	15.0
		% within Perdarahan SCBA	17.5%	20.0%	18.8%
gastritis	Tidak	Count	33	32	65
		Expected Count	32.5	32.5	65.0
		% within Perdarahan SCBA	82.5%	80.0%	81.3%
Total		Count	40	40	80
		Expected Count	40.0	40.0	80.0
		% within Perdarahan SCBA	100.0%	100.0%	100.0%

Chi-Square Tests

	Value	df	Asymp. Sig. (2-sided)	Exact Sig. (2-sided)	Exact Sig. (1-sided)
Pearson Chi-Square	.082 ^a	1	.775		
Continuity Correction ^b	.000	1	1.000		
Likelihood Ratio	.082	1	.774		
Fisher's Exact Test				1.000	.500
Linear-by-Linear Association	.081	1	.776		
N of Valid Cases	80				

a. 0 cells (.0%) have expected count less than 5. The minimum expected count is 7.50.

b. Computed only for a 2x2 table

Risk Estimate

	Value	95% Confidence Interval	
		Lower	Upper
Odds Ratio for gastritis (Ya / Tidak)	.848	.275	2.613
For cohort Perdarahan SCBA = Ya	.919	.509	1.661
For cohort Perdarahan SCBA = Tidak	1.083	.635	1.848
N of Valid Cases	80		

Diabetes Mellitus * Perdarahan SCBA Crosstabulation

			Perdarahan SCBA		Total
			Ya	Tidak	
Diabetes Mellitus	Ya	Count	9	13	22
		Expected Count	11.0	11.0	22.0
		% within Perdarahan SCBA	22.5%	32.5%	27.5%
	Tidak	Count	31	27	58
		Expected Count	29.0	29.0	58.0
		% within Perdarahan SCBA	77.5%	67.5%	72.5%
Total	Count	40	40	80	
	Expected Count	40.0	40.0	80.0	
	% within Perdarahan SCBA	100.0%	100.0%	100.0%	

Chi-Square Tests

	Value	df	Asymp. Sig. (2-sided)	Exact Sig. (2-sided)	Exact Sig. (1-sided)
Pearson Chi-Square	1.003 ^a	1	.317		
Continuity Correction ^b	.564	1	.453		
Likelihood Ratio	1.007	1	.316		
Fisher's Exact Test				.453	.227
Linear-by-Linear Association	.991	1	.320		
N of Valid Cases	80				

a. 0 cells (.0%) have expected count less than 5. The minimum expected count is 11.00.

b. Computed only for a 2x2 table

Risk Estimate

	Value	95% Confidence Interval	
		Lower	Upper
Odds Ratio for Diabetes Mellitus (Ya / Tidak)	.603	.223	1.630
For cohort Perdarahan SCBA = Ya	.765	.439	1.336
For cohort Perdarahan SCBA = Tidak	1.269	.814	1.978
N of Valid Cases	80		

Proton Pump Inhibitor * Perdarahan SCBA Crosstabulation

			Perdarahan SCBA		Total
			Ya	Tidak	
Proton Pump Inhibitor	Ya	Count	15	18	33
		Expected Count	16.5	16.5	33.0
		% within Perdarahan SCBA	37.5%	45.0%	41.3%
	Tidak	Count	25	22	47
		Expected Count	23.5	23.5	47.0
		% within Perdarahan SCBA	62.5%	55.0%	58.8%
Total	Count	40	40	80	
	Expected Count	40.0	40.0	80.0	
	% within Perdarahan SCBA	100.0%	100.0%	100.0%	

Chi-Square Tests

	Value	df	Asymp. Sig. (2-sided)	Exact Sig. (2-sided)	Exact Sig. (1-sided)
Pearson Chi-Square	.464 ^a	1	.496		
Continuity Correction ^b	.206	1	.650		
Likelihood Ratio	.465	1	.495		
Fisher's Exact Test				.650	.325
Linear-by-Linear Association	.458	1	.498		
N of Valid Cases	80				

a. 0 cells (.0%) have expected count less than 5. The minimum expected count is 16.50.

b. Computed only for a 2x2 table

Risk Estimate

	Value	95% Confidence Interval	
		Lower	Upper
Odds Ratio for Proton Pump Inhibitor (Ya / Tidak)	.733	.300	1.791
For cohort Perdarahan SCBA = Ya	.855	.539	1.354
For cohort Perdarahan SCBA = Tidak	1.165	.754	1.802
N of Valid Cases	80		

Histamine H2 receptor * Perdarahan SCBA Crosstabulation

			Perdarahan SCBA		Total
			Ya	Tidak	
Histamine H2 receptor	Ya	Count	13	11	24
		Expected Count	12.0	12.0	24.0
		% within Perdarahan SCBA	32.5%	27.5%	30.0%
	Tidak	Count	27	29	56
		Expected Count	28.0	28.0	56.0
		% within Perdarahan SCBA	67.5%	72.5%	70.0%
Total	Count	40	40	80	
	Expected Count	40.0	40.0	80.0	
	% within Perdarahan SCBA	100.0%	100.0%	100.0%	

Chi-Square Tests

	Value	df	Asymp. Sig. (2-sided)	Exact Sig. (2-sided)	Exact Sig. (1-sided)
Pearson Chi-Square	.238 ^a	1	.626		
Continuity Correction ^b	.060	1	.807		
Likelihood Ratio	.238	1	.625		
Fisher's Exact Test				.808	.404
Linear-by-Linear Association	.235	1	.628		
N of Valid Cases	80				

a. 0 cells (.0%) have expected count less than 5. The minimum expected count is 12.00.

b. Computed only for a 2x2 table

Risk Estimate

	Value	95% Confidence Interval	
		Lower	Upper
Odds Ratio for Histamine H2 receptor (Ya / Tidak)	1.269	.487	3.311
For cohort Perdarahan SCBA = Ya	1.123	.711	1.775
For cohort Perdarahan SCBA = Tidak	.885	.535	1.464
N of Valid Cases	80		

Crosstab

			Chronic Kidney Disease		Total
			Ya	Tidak	
Perdarahan SCBA	Ya	Count	11	29	40
		Expected Count	10.5	29.5	40.0
		% within Chronic Kidney Disease	52.4%	49.2%	50.0%
	Tidak	Count	10	30	40
		Expected Count	10.5	29.5	40.0
		% within Chronic Kidney Disease	47.6%	50.8%	50.0%
Total	Count		21	59	80
	Expected Count		21.0	59.0	80.0
	% within Chronic Kidney Disease		100.0%	100.0%	100.0%

Chi-Square Tests

	Value	df	Asymp. Sig. (2-sided)	Exact Sig. (2-sided)	Exact Sig. (1-sided)
Pearson Chi-Square	.065 ^a	1	.799		
Continuity Correction ^b	.000	1	1.000		
Likelihood Ratio	.065	1	.799		
Fisher's Exact Test				1.000	.500
Linear-by-Linear Association	.064	1	.801		
N of Valid Cases	80				

a. 0 cells (.0%) have expected count less than 5. The minimum expected count is 10.50.

b. Computed only for a 2x2 table

Risk Estimate

	Value	95% Confidence Interval	
		Lower	Upper
Odds Ratio for Perdarahan SCBA (Ya / Tidak)	1.138	.420	3.084
For cohort Chronic Kidney Disease = Ya	1.100	.527	2.296
For cohort Chronic Kidney Disease = Tidak	.967	.744	1.256
N of Valid Cases	80		

Crosstab

			Chronic Heart Failure		Total
			Ya	Tidak	
Perdarahan SCBA	Ya	Count	5	35	40
		Expected Count	6.0	34.0	40.0
		% within Chronic Heart Failure	41.7%	51.5%	50.0%
	Tidak	Count	7	33	40
		Expected Count	6.0	34.0	40.0
		% within Chronic Heart Failure	58.3%	48.5%	50.0%
Total	Count	12	68	80	
	Expected Count	12.0	68.0	80.0	
	% within Chronic Heart Failure	100.0%	100.0%	100.0%	
	Failure				

Chi-Square Tests

	Value	df	Asymp. Sig. (2-sided)	Exact Sig. (2-sided)	Exact Sig. (1-sided)
Pearson Chi-Square	.392 ^a	1	.531		
Continuity Correction ^b	.098	1	.754		
Likelihood Ratio	.394	1	.530		
Fisher's Exact Test				.755	.378
Linear-by-Linear Association	.387	1	.534		
N of Valid Cases	80				

a. 0 cells (.0%) have expected count less than 5. The minimum expected count is 6.00.

b. Computed only for a 2x2 table

Risk Estimate

	Value	95% Confidence Interval	
		Lower	Upper
Odds Ratio for Perdarahan SCBA (Ya / Tidak)	.673	.194	2.333
For cohort Chronic Heart Failure = Ya	.714	.247	2.063
For cohort Chronic Heart Failure = Tidak	1.061	.882	1.276
N of Valid Cases	80		

ANALISIS MULTIVARIAT

Variables in the Equation

	B	S.E.	Wald	df	Sig.	Exp(B)	95% C.I. for EXP(B)	
							Lower	Upper
Step 1 ^a Clopidogrel	-1.094	1.141	.919	1	.338	.335	.036	3.135
duraspr	3.264	.913	12.793	1	.000	26.151	4.373	156.398
durclo	1.919	1.019	3.546	1	.060	6.812	.925	50.188
Hipertensi	-1.839	.946	3.781	1	.052	.159	.025	1.015
Constant	-3.552	2.713	1.714	1	.190	.029		

a. Variable(s) entered on step 1: Clopidogrel, duraspr, durclo, Hipertensi.

BIODATA

Identitas

Nama : Damayanti Ika Prasanti
NIM : G2A009057
Tempat/Tanggal lahir : Tegal/24 Agustus 1991
Jenis Kelamin : Perempuan
Alamat : Jl. Banjaranyar No.40 Tegal
Nomor Telpon : (0283) 462833
Nomor HP : 085728279252
Email : damayanti_ip@yahoo.com

Riwayat Pendidikan Formal

1. SD : SD BALAPULANG 2 Lulus Tahun : 2003
2. SMP : SMPN 1 SLAWI Lulus Tahun : 2006
3. SMA : SMAN 3 SURAKARTA Lulus Tahun : 2009
4. FK UNDIP : Masuk Tahun : 2009

Keanggotaan Organisasi

1. BK RHEU UNDIPTahun : 2009 s/d 2011